…
Charlotte's Web Holdings, Inc. engages in the farming, manufacturing, marketing, and sale of hemp-derived cannabidiol (CBD) and other botanical-based wellness products. Its product categories include full-spectrum hemp extract oil tinctures, such as liquid products; gummies; capsules; soft-gels; CBD topical creams and lotions; broad-spectrum botanical CBD; functional mushrooms; and pet products under the Charlotte's Web, CBD CLINIC, and CBD MEDIC brand names. The company's products contain naturally occurring phytocannabinoids, including CBD, cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), terpenes, flavonoids, and other beneficial hemp compounds. It distributes its products through retail outlets, health care practitioners, and distributors, as well as online through its website and other third-party e-commerce sites. The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte's Web Holdings, Inc. in July 2018. Charlotte's Web Holdings, Inc. was founded in 2013 and is headquartered in Louisville, Colorado.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Charlotte's Web Holdings Inc produces and sells hemp-derived CBD wellness products for people and pets via direct-to-consumer and retail channels. Long-term growth drivers include rising consumer adoption of CBD, product innovation and expansion into new channels and markets, and the company's established brand may support distribution reach.
Key risks are regulatory uncertainty over CBD ingestibles, strong competition from larger consumer packaged goods players, and commodity and margin pressure.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -29.81M | -29.81M | -23.27M | -59.22M | -137.58M |
| Net income | -29.74M | -29.85M | -23.80M | -59.31M | -137.72M |
| Selling general administrative | 41.97M | 41.58M | 61.85M | 65.80M | 91.12M |
| Selling and marketing expenses | - | 7.98M | 13.78M | - | - |
| Gross profit | 21.70M | 21.26M | 35.57M | 19.41M | 48.59M |
| Reconciled depreciation | 6.32M | 9.98M | 15.16M | 8.97M | 11.03M |
| Ebit | -20.27M | -31.99M | -40.06M | -50.65M | 39.52M |
| Ebitda | -13.95M | -22.01M | -24.90M | -32.36M | 50.54M |
| Depreciation and amortization | 6.32M | 9.98M | 15.16M | 18.29M | 11.03M |
| Operating income | -20.27M | -31.99M | -40.61M | -50.65M | 39.52M |
| Other operating expenses | 70.17M | 81.65M | 103.77M | 124.79M | 145.15M |
| Interest expense | - | - | - | 17.89M | 177.10M |
| Tax provision | -0.07M | 0.04M | 0.53M | 0.09M | 0.14M |
| Interest income | - | 0.61M | 20.04M | 7.48M | 9.43M |
| Income tax expense | -0.07M | 0.04M | 0.53M | 0.09M | 0.14M |
| Total revenue | 49.90M | 49.67M | 63.16M | 74.14M | 96.09M |
| Total operating expenses | 41.97M | 53.25M | 76.18M | 70.06M | 97.64M |
| Cost of revenue | 28.20M | 28.41M | 27.59M | 54.73M | 47.51M |
| Total other income expense net | -9.54M | 2.18M | 17.34M | -8.57M | -177.10M |
| Net income from continuing ops | -29.74M | -29.85M | -23.80M | -59.31M | -137.72M |
| Net income applicable to common shares | - | -29.85M | -23.80M | -59.31M | -137.72M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 75.27M | 113.44M | 152.55M | 187.64M | 171.51M |
| Intangible assets | 0.79M | 14.74M | 17.96M | 28.64M | 2.84M |
| Other current assets | 1.77M | 1.00M | 2.50M | 2.50M | 7.15M |
| Total liab | 77.31M | 86.36M | 96.99M | 110.14M | 41.07M |
| Total stockholder equity | -2.04M | 27.09M | 55.56M | 77.50M | 130.45M |
| Other current liab | 5.05M | - | 20.79M | 15.10M | 13.02M |
| Common stock | 0.00M | - | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -331.31M | -301.57M | -271.72M | -247.93M | -188.61M |
| Other liab | - | - | - | - | 0.40M |
| Good will | - | - | - | - | 0.00M |
| Other assets | - | - | - | 9.39M | 16.10M |
| Cash | 8.04M | 22.62M | 47.82M | 66.96M | 19.49M |
| Cash and equivalents | - | - | - | 66.96M | 19.49M |
| Total current liabilities | 8.66M | 15.94M | 23.65M | 21.43M | 20.17M |
| Current deferred revenue | - | - | -2.25M | - | - |
| Net debt | 56.42M | 21.01M | 12.62M | -9.33M | 3.11M |
| Short term debt | 1.42M | - | 2.25M | 2.31M | 2.10M |
| Short long term debt total | 64.45M | - | 60.44M | 57.63M | 22.60M |
| Other stockholder equity | 329.27M | - | 327.28M | 325.43M | 319.06M |
| Property plant equipment | - | - | - | 45.85M | 56.76M |
| Total current assets | 30.36M | 46.98M | 78.17M | 103.76M | 95.81M |
| Long term investments | 8.80M | 10.80M | 11.00M | - | 13.00M |
| Net tangible assets | - | - | - | 48.86M | 127.60M |
| Short term investments | - | - | 1.17M | - | - |
| Net receivables | 2.54M | 1.26M | 2.33M | 2.42M | 17.09M |
| Long term debt | 50.85M | 43.63M | 42.53M | 37.43M | 0.39M |
| Inventory | 18.02M | 18.91M | 21.54M | 26.95M | 52.08M |
| Accounts payable | 2.19M | 3.43M | 2.86M | 4.02M | 5.05M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Non currrent assets other | 1.35M | 0.63M | 0.70M | 9.39M | 3.10M |
| Non current assets total | 44.91M | 79.34M | 74.38M | 83.88M | 75.71M |
| Capital lease obligations | 13.61M | 15.71M | 17.91M | 20.21M | 22.60M |
| Long term debt total | - | - | - | 37.43M | 20.89M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -3.80M | -3.51M | 0.40M | -11.79M |
| Change to liabilities | - | - | - | 0.00M | -2.91M |
| Total cashflows from investing activities | -0.41M | -3.80M | -3.51M | 0.40M | -11.79M |
| Total cash from financing activities | -0.05M | -0.14M | -0.25M | 52.39M | 8.04M |
| Change to operating activities | - | - | - | - | -6.51M |
| Net income | -29.74M | -29.85M | -23.80M | -59.31M | -137.72M |
| Change in cash | -14.58M | -25.20M | -19.14M | 47.47M | -33.31M |
| Begin period cash flow | 22.62M | 47.82M | 66.96M | 19.49M | 52.80M |
| End period cash flow | 8.04M | 22.62M | 47.82M | 66.96M | 19.49M |
| Total cash from operating activities | -14.12M | -21.26M | -15.39M | -5.32M | -29.56M |
| Issuance of capital stock | - | - | - | - | 8.26M |
| Depreciation | 6.32M | 9.98M | 15.16M | 8.97M | 11.03M |
| Other cashflows from investing activities | 0.14M | 0.06M | 0.18M | 0.66M | -6.88M |
| Change to inventory | 0.11M | -1.52M | 4.38M | 1.73M | 1.02M |
| Change to account receivables | 0.37M | 0.36M | 3.45M | 2.95M | -0.95M |
| Sale purchase of stock | - | - | - | -0.06M | 8.29M |
| Other cashflows from financing activities | -0.05M | -0.14M | -0.25M | 52.45M | -0.22M |
| Change to netincome | - | - | - | - | 105.81M |
| Capital expenditures | 0.55M | 3.85M | 3.69M | 0.27M | 4.92M |
| Change in working capital | -3.28M | -9.07M | -1.87M | 4.77M | -8.67M |
| Stock based compensation | 0.66M | 1.52M | 2.10M | 3.40M | 5.48M |
| Other non cash items | 11.91M | 6.15M | -6.98M | 36.86M | 100.33M |
| Free cash flow | -14.67M | -25.11M | -19.08M | -5.58M | -34.48M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CWEB Charlotte's Web Holdings Inc |
0.01 4.92% |
0.32 | - | 58.82 | 2.70 | 12.40 | 3.08 | -2.70 |
| CURA Curaleaf Holdings Inc. |
1.23 9.59% |
14.06 | - | 138.89 | 2.57 | 3.14 | 2.47 | 13.10 |
| BHC Bausch Health Companies Inc |
0.12 1.07% |
11.37 | 13.98 | 1.35 | 0.28 | 18.74 | 2.12 | 6.84 |
| CRON Cronos Group Inc |
0.06 1.28% |
4.76 | - | 32.15 | 9.80 | 0.95 | 1.47 | 1.90 |
| TLRY Tilray Inc |
0.13 3.66% |
3.68 | - | 1000.00 | 1.28 | 0.53 | 1.08 | -2.30 |
Charlotte's Web Holdings, Inc. engages in the farming, manufacturing, marketing, and sale of hemp-derived cannabidiol (CBD) and other botanical-based wellness products. Its product categories include full-spectrum hemp extract oil tinctures, such as liquid products; gummies; capsules; soft-gels; CBD topical creams and lotions; broad-spectrum botanical CBD; functional mushrooms; and pet products under the Charlotte's Web, CBD CLINIC, and CBD MEDIC brand names. The company's products contain naturally occurring phytocannabinoids, including CBD, cannabichromene (CBC), cannabigerol (CBG), cannabinol (CBN), terpenes, flavonoids, and other beneficial hemp compounds. It distributes its products through retail outlets, health care practitioners, and distributors, as well as online through its website and other third-party e-commerce sites. The company was formerly known as Stanley Brothers Holdings Inc. and changed its name to Charlotte's Web Holdings, Inc. in July 2018. Charlotte's Web Holdings, Inc. was founded in 2013 and is headquartered in Louisville, Colorado.
| Name | Title | Year Born |
|---|---|---|
| Mr. Jacques Tortoroli | CEO, Pres & Director | 1959 |
| Mr. Jared Stanley | Co-Founder & COO | 1988 |
| Mr. Greg Gould | CFO & Chief Admin. Officer | NA |
| Mr. Andres de Gortari | Chief Accounting Officer | 1976 |
| Cory Pala | Director of Investor Relations | NA |
| Mr. Stephen David Rogers | Sr. VP, Gen. Counsel & ?Corp. Sec.. | 1966 |
| Ms. Kelly Shea | Sr. VP of Gov. Affairs & Corp. Communications | NA |
| Mr. Richard L. Mohr | Advisor | 1960 |
| Mr. Tim Orr | Sr. VP of Innovation | NA |
| Mr. Perry Antelman | Exec. VP & Pres of Topicals | 1964 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.